Reneo Pharmaceuticals Announces Definitive Agreement, Equity Sales

Ticker: OKUR · Form: 8-K · Filed: May 13, 2024 · CIK: 1637715

Sentiment: neutral

Topics: material-agreement, equity-sale, change-of-control

TL;DR

Reneo Pharma inked a deal, sold some stock, and might have a new boss. Big moves happening.

AI Summary

Reneo Pharmaceuticals, Inc. announced on May 10, 2024, that it entered into a Material Definitive Agreement. The filing also disclosed unregistered sales of equity securities and changes in control of the registrant. Additionally, there were changes in directors and officers, along with compensatory arrangements for certain officers.

Why It Matters

This filing indicates significant corporate actions, including a material agreement and potential changes in control, which could impact the company's strategic direction and shareholder value.

Risk Assessment

Risk Level: medium — The filing mentions unregistered sales of equity and changes in control, which can introduce uncertainty and potential risks for investors.

Key Players & Entities

FAQ

What is the nature of the Material Definitive Agreement entered into by Reneo Pharmaceuticals?

The filing states that Reneo Pharmaceuticals, Inc. entered into a Material Definitive Agreement on May 10, 2024, but the specific details of the agreement are not provided in this summary.

What type of equity securities were sold unregistered?

The filing indicates unregistered sales of equity securities occurred, but does not specify the type or amount of securities sold.

What changes in control of Reneo Pharmaceuticals are being reported?

The filing notes that there were changes in control of the registrant, but does not provide specific details about these changes.

Are there any new directors or officers appointed, or any departing?

The filing reports on the departure of directors or certain officers, the election of directors, and the appointment of certain officers.

What is the primary business of Reneo Pharmaceuticals, Inc. according to the filing?

Reneo Pharmaceuticals, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.

Filing Stats: 4,738 words · 19 min read · ~16 pages · Grade level 17.3 · Accepted 2024-05-13 09:14:11

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed business combination involving Reneo and OnKure, the Concurrent PIPE Investment and any related proposed transactions (collectively, the " Proposed Transactions "). Any statements contained in this Current Report that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements generally are accompanied by words such as "anticipate," "believe," "continue," "estimate," "expect," "future," "goal," "intend," "may," "outlook," "plan," "potential," "predict," "project," "seem," "seek," "should," "target," "will," "would," and similar expressions that indicate future events or trends or that are not statements of historical matters. These forward-looking statements may include, but are not limited to, statements regarding the Proposed Transactions; the combined company's capitalization and the planned use of proceeds following the Proposed Transactions; the expected executive officers and directors of the combined company; the potential of, and plans and expectations regarding, the combined company's product candidates; the development of the combined company's current and future product candidates; the future operations of Reneo, OnKure and the combined company; and the commercial potential of the combined company's product candidates, including any anticipated milestones. These statements are based on various assumptions, whether or not identified in this Current Report, and on the current expectations of Reneo's and OnKure's management and are not assurances as to actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing